A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)

NCT04537806 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

29

Enrollment

INDUSTRY

Sponsor class

Stopped Internal company decision

Conditions

Acute Respiratory Distress Syndrome
COVID-19

Interventions

DRUG: Brexanolone
DRUG: Placebo

Sponsor

Sage Therapeutics